Suggestions
Michael Florea
PhD Student at Harvard Medical School
Michael Florea is a highly accomplished professional in the field of biology, with a strong educational background and diverse research experience.
He holds a Doctor of Philosophy (PhD) in Biology/Biological Sciences from Harvard University, a Master of Science (MSc) in Biotechnology from Eidgenössische Technische Hochschule Zürich, and a Bachelor of Science (BSc) in Biology from Imperial College London.
During his academic journey, Michael has been actively involved in various prestigious organizations. He has contributed to research as a PhD Student at Harvard Medical School and as an MSc Student at Fussenegger Lab, D-BSSE, ETH Zürich.
Moreover, Michael has significant entrepreneurial experience, having co-founded Genetic Engineering R&D at CustoMem and served as the co-founder and President at SynBIC.
His professional journey also includes roles as an Undergraduate Student and Researcher at Imperial College London, as well as research positions at the Natural History Museum and the University of Zurich.
Michael Florea's multidisciplinary background and hands-on experience in both academia and industry underscore his expertise and passion for advancing the field of biology.
Highlights
Why would anyone leave a scientific career to go build ... mouse tech?
90.4% of drugs fail in humans. It costs $2.3B and takes 12 years to get a drug to market. Only ~50 new drugs are approved per year in the entirety of the US.
Animal studies determine what goes into humans. If you can reduce the failure rate by 2% (from 90% to 88%), resulting in 10 more drugs/year, you will have the impact of a major pharmaceutical conglomerate.
Many things can be done to improve translation that aren't being done. At the moment, we don't even know what works in mice, since at current economics, studies are rarely replicated.
Many more people should be thinking about this. Deep dive below.
Thank you to Cecilia Kruszynski de Assis for the insightful questions. https://lnkd.in/gBN-NUiq
A basic mouse longevity study costs half a million when outsourced.
That’s because the state of the art in animal research is measuring one animal at a time, by hand, and writing the data on a piece of paper. So, you need a team of technicians to get even a basic health dataset. As an example, in my PhD, I ran 4 studies - but it took me 8 full months of doing solely exhausting manual measurements all day, every day.
As a consequence, few quality studies are published each year. Most are underpowered. Very few are ever replicated. Yet a study in a mammal (usually mouse) is the data that people rely on to consider something potentially effective, and in longevity, try it on themselves. This is a fundamental bottleneck.
So today, exactly 1 year after my PhD defense, we’re launching Olden Labs - a company building the world's first automated animal lab. Our goal is to radically accelerate animal research for mankind, by bringing down the costs, time and accessibility barriers and removing the lack of reproducibility inherent in manual testing.
As our first technology, we’re releasing the DOME smart cage: a device that gives 24/7 data on 14+ metrics of animal’s health and can be installed in existing infrastructure. At <$1k, it is 30x cheaper than the nearest competitor, can measure multiple animals instead of one (no RFID), and can do this indefinitely instead of a few weeks max. We’ve used it to create the v1 of “digital bioage” - a metric that tracks the chronological age of animals by summarizing overall health. Accessible here: https://oldenlabs.com/
I’m incredibly fortunate to be joined by my co-founders Noah Weber (ex-CTO of CelerisTx and an AI 30U30), Michael Kaca (ex-Apple) and Pratomo Putra Alimsijah (ex-10x Genomics), and our external tech team Sead Delalić and Eldina Delalić (Uni. of Sarajevo) - the team behind this tech.
We’re also privileged to be supported by Charles Hirschler (CHBMR Partners, Harvard bioelectronics), Amy Wagers (Harvard Prof Stem Cell biology & aging), Kathleen Pritchett-Corning (Harvard Director of Animal studies), Vadim Gladyshev (Harvard Prof Systems Aging), Tyler Cowen (Mercatus Center’s Emergent Ventures), Nathan Cheng and Sebastian A. Brunemeier (Healthspan Capital), Niklas Anzinger (Infinita Fund), and many others. They make the highs worth it and the lows bearable. Finally, thanks to Danny Sullivan at Longevity Technology for the awesome article!
So, join us on the journey and let's make a dent.
https://lnkd.in/ggJ55VWE #longevity #animalresearch #biotechnology #AI
